ClinicalTrials.gg
CompletedNCT00378144Updated Jul 10, 2012

Efficacy and Safety of Sinutab on Subjects in the Setting of a Common Cold

A Phase 4 interventional study of Pseudoephedrine/Paracetamol in Common Cold, Headache and Nasal Congestion, sponsored by McNeil AB. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-10.

Sponsored by McNeil AB (formerly part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the efficacy and safety for a marketed sinus allergy product, Sinutab, in the treatment of nasal congestion and headache.

Read the detailed description

In response to a mandated requirement from the Belgium Medicines Agency - rising from the perforce switch of Sinutab® to a 2 active ingredients Pseudoephedrine+Paracetamol combination - we have made a commitment to demonstrate the safety and efficacy of Sinutab®.

In agreement with the Medicines Agency, an in-use Pharmacy-based study has been designed to demonstrate efficacy and safety of Sinutab® for the approved indications (symptomatic relief in the common cold).

This will be a randomized, double blind, placebo-controlled, comparative phase 4, multi-centre study in parallel groups between Sinutab and placebo. To study the drug in it's 'natural environment', community pharmacists will function as local investigators. Approximately 25 community pharmacists will be carefully selected, and only be taken into consideration if appropriate software programs are used in their pharmacy.

This implicates that the pharmacist has a medication record of his patients at his disposal which he will use to check the exclusion criteria. They will include subjects with early (≤ 48 hours) cold symptoms of blocked nose with headache. Subjects fulfilling the inclusion/exclusion criteria will be assigned to one of the two treatment groups, according to a computer-generated randomization list. A sufficient number of subjects will be randomized in the order of their enrolment, targeting at 300 evaluable subjects at the conclusion of study.

The following information will be collected every evening from subjects during 7 days: symptom assessment, compliance, adverse events and the ability to go to work or school.

02

Conditions studied

  • Common Cold
  • Headache
  • Nasal Congestion
03

In context

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

This study's enrollment of 469 is above the median of 150 across 184 interventional studies indexed under Common Cold.

Browse Common Cold studies →

Lead sponsor

McNeil AB is the lead sponsor of 42 studies on the registry; 1 is open to participants now.

First submitted before McNeil AB left Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 years or more
  • reported cold symptoms beginning ≤ 48 hours prior to visit 1
  • scored ≥ 2 for each of nasal congestion and headache using the Modified Jackson Subject Evaluation Scale
  • willing and able to comply with scheduled visits, treatment plan, and other study procedures
  • evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the trial

Exclusion criteria

Exclusion Criteria:

  • patients without an electronic medication record in the pharmacy
  • history of to paracetamol or pseudoephedrine or lactose
  • fever more than 38.0°C (measured by pharmacist)
  • women in the fertile years who do not use a hormonal or an intra-uterine device
  • use of concomitant drugs, medications or treatments that could interfere with the study drug
  • important intercurrent medical condition based on the available medication record of the patient. (cf. exclusion criterium 1)
  • history of nasal reconstructive surgery
  • alcohol and/or drug abuse within a 6-month period immediately preceding the screening visit
  • any medication or indication that might point to an increased risk, associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion
  • participation in other clinical trials the last three months and during study participation.
  • employees of the clinical research centers, sponsor, the CRO's contracted for this study, or their immediate family members
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
469 participants (actual)

Study arms

  • Experimental
    1

    Pseudoephedrine/Paracetamol

    Drug: Pseudoephedrine/Paracetamol

Interventions

  • DrugPseudoephedrine/Paracetamol

    Drug pages: Pseudoephedrine · Acetaminophen

    Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]

    Also known as: Sinutab

06

What researchers measure

Primary outcomes

  1. Change from baseline in the sum of nasal congestion and headache sign/symptom scores

    Time frame: 7 days

Secondary outcomes

  1. Change from baseline in the mean MSC score over the treatment days. The MSC score is defined as the sum of nasal congestion, headache, sore throat, and pressure around the eyes sign/symptom scores

    Time frame: 7 days

  2. Change from baseline in the mean individual sign/symptom score, including nasal congestion, headache, sore throat, and pressure around the eyes

    Time frame: 7 days

  3. Number of lost days at work or school

    Time frame: 7 Days

  4. Mean scores for: (a) interference with concentration; and (b) interference with sleep for days during treatment with study medication only

    Time frame: 7 days

  5. Safety evaluation by adverse event recording

    Time frame: 7 days

  6. Exploratory Endpoint: time to reach the first of two consecutive total Modified Jackson Subject Evaluation Scale (MJS) scores (defined as sum of 8 signs/symptoms) ≤ 1

    Time frame: Up to seven days

07

Study locations

1 site
  • JJCPPW Investigational Site
    Wilrijk, Antwerp, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2006
First posted
Sep 19, 2006
Start
Jan 2007
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Jul 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00378144
Lead sponsor
McNeil AB
Responsible party
Sponsor
First posted
Sep 19, 2006
Start date
Jan 2007
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Jul 10, 2012

Study contacts

Elisabeth A Kruse, PhD
study director · JJCPPW

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pseudoephedrine · Acetaminophen

Start the discussion